We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · March 05, 2021

Azacitidine Does Not Impact Prognosis in Intermediate-Risk Myelodysplastic Syndromes

Blood Cancer Journal

 

Additional Info

Blood Cancer Journal
Refinement of Prognosis and the Effect of Azacitidine in Intermediate-Risk Myelodysplastic Syndromes
Blood Cancer J 2021 Feb 11;11(2)30, K Liapis, V Papadopoulos, G Vrachiolias, AG Galanopoulos, M Papoutselis, SG Papageorgiou, PT Diamantopoulos, V Pappa, NA Viniou, A Kourakli, D Τsokanas, TP Vassilakopoulos, E Hatzimichael, E Bouronikou, M Ximeri, C Pontikoglou, A Megalakaki, P Zikos, P Panayiotidis, M Dimou, S Karakatsanis, M Papaioannou, A Vardi, F Kontopidou, N Harchalakis, I Adamopoulos, A Symeonidis, I Kotsianidis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading